Connect Biopharma Holdings Limited (NASDAQ:CNTB – Get Free Report) saw a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 45,500 shares, an increase of 26.7% from the September 30th total of 35,900 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 27,300 shares, the short-interest ratio is currently 1.7 days.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Connect Biopharma in a research report on Friday, September 6th.
Check Out Our Latest Analysis on CNTB
Connect Biopharma Stock Performance
Institutional Investors Weigh In On Connect Biopharma
An institutional investor recently raised its position in Connect Biopharma stock. Keudell Morrison Wealth Management raised its holdings in shares of Connect Biopharma Holdings Limited (NASDAQ:CNTB – Free Report) by 63.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,200 shares of the company’s stock after buying an additional 12,500 shares during the period. Keudell Morrison Wealth Management owned about 0.06% of Connect Biopharma worth $49,000 at the end of the most recent reporting period. 58.72% of the stock is currently owned by institutional investors.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
Featured Stories
- Five stocks we like better than Connect Biopharma
- The Risks of Owning Bonds
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- How to Effectively Use the MarketBeat Ratings Screener
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Ride Out The Recession With These Dividend KingsĀ
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.